Efficacy of a combination of dutasteride, tadalafil, and solifenacin in the treatment of previously unsuccessful patients

doi:10.1016/j.ajur.2021.04.002

Asian Journal of Urology, 2022, 9 (1): 42-50 doi: 10.1016/j.ajur.2021.04.002

Original Articles

Efficacy of a combination of dutasteride, tadalafil, and solifenacin in the treatment of previously unsuccessful patients

Kirill Kosilov^a,b,*(

),Irina Kuzina^a,Vladimir Kuznetsov^c,Olga Barabash^d,Ekaterina Fedorishcheva^c

^a Department of Social Sciences, School of Humanities, Far Eastern Federal University, Vladivostok, Primorsky region, Russian Federation
^b Department of Clinical Medicine, School of Medicine, Far Eastern Federal University, Vladivostok, Primorsky region, Russian Federation
^c Department of Public Health, Pacific State Medical University, Vladivostok, Primorsky region, Russian Federation
^d Department of Physical Culture and Health and Sports Work, Vladivostok State University of Economics and Service, Vladivostok, Primorsky region, Russian Federation

Abstract
Related Citation (15)

Download:

HTML

PDF (815KB)
Export: BibTeX | EndNote (RIS)

Abstract

Objective: To evaluate the efficacy and safety of simultaneous administration of dutasteride, tadalafil and solifenacin in the treatment of benign prostatic hyperplasia (BPH) with overactive bladder symptoms and lower urinary tract obstruction in previously unsuccessfully treated men.
Methods: Patients in Group A (n=97) received dutasteride 0.5 mg/day, tadalafil 2.5 mg/day, and solifenacin 2.5 mg/day; Group B (n=95) received dutasteride 0.5 mg/day, tadalafil 5 mg/day, and solifenacin 5 mg/day; Group C (n=103) received dutasteride 0.5 mg/day, tadalafil 20 mg/day, and solifenacin 10 mg/day. The functional status of the lower urinary tract was assessed using the International Prostate Symptom Score (I-PSS), Overactive Bladder Questionnaire (OABq), International Index of Erectile Function (IIEF), and Male Sexual Health Questionnaire Ejaculatory Dysfunction (MSHQ-EjD) as well as uroflowmetry.
Results: The total score of the sexual function remained unchanged in Group B of patients 81.3 points vs. 80.2 points (p>0.05) according to MSHQ-EjD, 61.4 points vs. 51.2 points (p>0.05) according to IIEF data. The total assessment of symptoms of hyperactivity significantly decreased in Group C according to OABq data after the 4th week of the study (17.5 points vs. 26.1 points, p<0.05) and remained below the baseline until the end of the study (15.2 points).
Conclusions: The simultaneous administration of standard doses of dutasteride, solifenacin, and tadalafil for 3 months is safe, effective, and can be recommended for patients with BPH to reduce symptoms of obstruction and hyperactivity of the bladder and maintain sexual function.

Key words： Lower urinary tract symptoms Benign prostatic hyperplasia Dutasteride Tadalafil Solifenacin Sexual function

Received: 08 July 2019 Available online: 20 January 2022

Corresponding Authors: Kirill Kosilov E-mail: oton2000@mail.ru

	Service
	E-mail this article
	Add to citation manager
	E-mail Alert
	Articles by authors
	Kirill Kosilov
	Irina Kuzina
	Vladimir Kuznetsov
	Olga Barabash
	Ekaterina Fedorishcheva

TRENDMD:

Cite this article:

Kirill Kosilov,Irina Kuzina,Vladimir Kuznetsov, et al. Efficacy of a combination of dutasteride, tadalafil, and solifenacin in the treatment of previously unsuccessful patients[J]. Asian Journal of Urology, 2022, 9(1): 42-50.

URL:

http://www.ajurology.com/EN/10.1016/j.ajur.2021.04.002 OR http://www.ajurology.com/EN/Y2022/V9/I1/42

Physiological and socio-demographic characteristics in men with benign prostatic hyperplasia and lower urinary tract symptoms (n=295).

Study design (n=295). USoPG, ultrasound examination of the prostate gland; PSA, prostatic-specific antigen; I-PSS, International Prostate Symptom Score; OAB-AT, Overactive Bladder Awareness Tool; MSHQ-EjD, Men's Sexual Health Questionnaire Ejaculatory Dysfunction; IIEF, the International Index of Erectile Function; UF, uroflowmetry.

Symptoms of obstruction lower urinary tract in patients with benign prostate hyperplasia before and after treatment (n=295). (A) I-PSS before/after treatment, total score; (B) UF before/after treatment, Q_aver, mL/s. I-PSS, International Prostate Symptom Score; UF, uroflowmetry. ? Differences are statistically significant.

Symptoms of hyperactive lower urinary tract in patients with benign prostate hyperplasia before and after treatment (n=295; Group A: n=95; Group B: n=97; Group C: n=103). (A) OAB-questionnaire overall rating; (B) Voiding diaries, number of episodes. OAB, overactive bladder. ? Differences are statistically significant.

Symptoms of sexual dysfunction in patients with benign prostate hyperplasia before and after treatment (n = 295; Group A: n = 95; Group B: n = 97; Group C: n = 103). (A) The results according to the Men's Sexual Health Questionnaire; (B) The results according to the International Index of Erectile Function. ? Differences are statistically significant.

[1]	Vignozzi L, Rastrelli G, Corona G, Gacci M, Forti G, Maggi M. Benign prostatic hyperplasia: A new metabolic disease? J Endocrinol Invest 2014; 37:313e22.
[2]	Aaron LT, Franco OE, Hayward SW. Review of prostate anatomy and embryology and the etiology of benign prostatic hyperplasia. Urol Clin North Am 2016; 43:279e88.
[3]	Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011; 60:809e25.
[4]	Shih HJ, Huang CJ, Lin JA, Kao MC, Fan YC, Tsai PS. Hyperlipidemia is associated with an increased risk of clinical benign prostatic hyperplasia. Prostate 2018; 78:113e20.
[5]	Kanai A, Andersson KE. Bladder afferent signaling: Recent findings. J Urol 2010; 183:1288e95.
[6]	Rosen RC. Assessment of sexual dysfunction in patients with benign prostatic hyperplasia. BJU Int 2006; 97:29e33.
[7]	Spångberg A, Dahlgren H. [Benign prostatic hyperplasia with bladder outflow obstruction. A systematic review]. Lakartidningen 2013; 110:682e5. [Article in Swedish].
[8]	Hanuš T, Zámečník L, Dole_zal T, Karmazínová Z. Occurrence of overactive bladder in patients with benign prostatic hyperplasia in the Czech Republic. Urol Int 2011; 86:407e13.
[9]	Wang Y, Bao Y, Liu J, Duan L, Cui Y. Tadalafil 5 mg once daily improves lower urinary tract symptoms and erectile dysfunction: A systematic review and meta-analysis. Low Urin Tract Symptoms 2018; 10:84e92.
[10]	Pietrzyk B, Olszanecka-Glinianowicz M, Owczarek A, Gabryelewicz T, Almgren-Rachtan A, Prajsner A, et al. Depressive symptoms in patients diagnosed with benign prostatic hyperplasia. Int Urol Nephrol 2015; 47:431e40.
[11]	Jeong WS, Choi HY, Nam JW, Kim SA, Choi BY, Moon HS, et al. Men with severe lower urinary tract symptoms are at increased risk of depression. Int Neurourol J 2015; 19:286e92.
[12]	Nichol MB, Knight TK, Wu J, Barron R, Penson DF. Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol 2009; 181:2214e21.
[13]	Kosilov K, Loparev S, Kuzina I, Shakirova O, Zhuravskaya N, Lobodenko A. The effective tool for self-assessment of adherence to treatment in patients with benign prostatic obstruction and overactive bladder symptoms. Aging Male 2017; 20:39e44.
[14]	Kosilov K, Loparev S, Kuzina I, Shakirova O, Zhuravskaya N, Lobodenko A. Long-term adherence to antimuscarinic drugs when treating overactive bladder in the older: Subjective reason and objective factors. Investig Clin Urol 2017; 58:109e16.
[15]	Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: Prevalence and incident rates. Urol Clin North Am 2016; 43:289e97.
[16]	Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, et al. Benign prostatic hyperplasia. Nat Rev Dis Prim 2016; 2: 16031. https://doi.org/10.1038/nrdp.2016.31.
[17]	Drobnis EZ, Nangia AK. 5a-Reductase inhibitors (5ARIs) and male reproduction. Adv Exp Med Biol 2017; 1034:59e61.
[18]	Chung BH, Roehrborn CG, Siami P, Major-Walker K, Morrill BB, Wilson TH, et al. Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH. Prostate Cancer Prostatic Dis 2009; 12:152e9.
[19]	Gacci M, Andersson KE, Chapple C, Maggi M, Mirone V, Oelke M, et al. Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2016; 70:124e33.
[20]	Schauer I, Madersbacher S. Medical treatment of lower urinary tract symptoms/benign prostatic hyperplasia: Anything new in 2015. Curr Opin Urol 2015; 25:6e11.
[21]	Oelke M, Martinelli E. [Pharmacological treatment of benign prostatic hyperplasia]. Urologe A 2016; 55:81e94. [Article in German].
[22]	Chung DE, Te AE, Staskin DR, Kaplan SA. Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 g. Urology 2010; 75:1144e8.
[23]	Auffenberg GB, Helfand BT, McVary KT. Established medical therapy for benign prostatic hyperplasia. Urol Clin North Am 2009; 36:443e59.
[24]	Yamanishi T, Asakura H, Seki N, Tokunaga S. Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial. Int J Urol 2017; 24:525e31.
[25]	Felicilda-Reynaldo RF. A review of anticholinergic medications for overactive bladder symptoms. Medsurg Nurs 2013; 22:119e23.
[26]	Kosilov K, Loparev S, Kuzina I, Shakirova O, Zhuravskaya N, Lobodenko A. Treatment compliance of working persons to high-dose antimuscarinic therapies: A randomized trial. Ther Adv Urol 2016; 8:239e48.
[27]	Kosilov K, Loparev S, Ivanovskaya M, Kosilova L. Additional correction of OAB symptoms by two anti-muscarinics for men over 50 years old with residual symptoms of moderate prostatic obstruction after treatment with tamsulosin. Aging Male 2015; 18:44e8.
[28]	Ruffion A, Marionneau N, Taïeb C, Perrin P. Comparison of the response to I-PSS according to the mode of administration of the questionnaire: By the doctor or self-assessment by the patient. Prog Urol 2005; 15:1080e4.
[29]	Coyne KS, Margolis MK, Bavendam T, Roberts R, Elinoff V. Validation of a 3-item OAB awareness tool. Int J Clin Pract 2011; 65:219e24.
[30]	Kosilov K, Loparev S, Ivanovskaya M, Kosilova L. Comparative effectiveness of combined low- and standard-dose trospium and solifenacin for moderate overactive bladder symptoms in elderly men and women. Urol Int 2014; 93:470e3.
[31]	Chen H, Wang F, Yu Z, Zhang Y, Liu C, Dai S, et al. Efficacy of daily low-dose tadalafil for treating overactive bladder: Results of a randomized, double-blind, placebo-controlled trial. Urology 2017; 100:59e64.
[32]	Kosilov K, Kuzina I, Kuznetsov V, Gainullina Y, Kosilova L, Prokofyeva A, et al. Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage. Aging Male 2018; 21:121e9.
[33]	Ricardi U, Gontero P, Ciammella P, Badellino S, Valentino F, Munoz F, et al. Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of postradiotherapy erectile dysfunction in prostate cancer men: A randomized phase II trial. J Sex Med 2010; 7:2851e9.
[34]	Singh G, Lucas M, Dolan L, Knight S, Ramage C, Hobson Ph. Minimum standards for urodynamic practice in the UK. Neurol Urodyn 2010; 29:1365e72.
[35]	Parsons M, Amundsen CL, Cardozo L, Vella M, Webster GD, Coats AC. Bladder diary patterns in detrusor overactivity and urodynamic stress incontinence. Neurourol Urodyn 2007; 26:800e6.
[36]	Chun JY, Song M, Han JY, Na S, Hong B, Choo MS. Clinical factors associated with dose escalation of solifenacin for the treatment of overactive bladder in real life practice. Int Neurourol J 2014; 18:23e30.
[37]	Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV. Comparative effectiveness of combined high-dosed trospium and solifenacin for severe OAB symptoms in age-related aspect. Urol Int 2014; 93:470e3.
[38]	Homma Y, Gotoh M, Kawauchi A, Kojima Y, Masumori N, Nagai A, et al. Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. Int J Urol 2017; 24:716e29.